Eli Lil­ly joins a troi­ka of Big Phar­mas that have tied up to a low-pro­file biotech with big as­pi­ra­tions in au­toim­mune dis­ease, can­cer

Eli Lil­ly has fol­lowed 3 ma­jor league phar­ma play­ers down the deal path to Im­muNext, a biotech you may not know a whole lot about.

The low-pro­file biotech has re­served one seg­ment of the R&D mis­sion for im­munome­tab­o­lism, study­ing how you could reg­u­late the im­mune sys­tem so that it would stop at­tack­ing healthy tis­sue, of­fer­ing a new ap­proach to au­toim­mune dis­eases. Their pre­clin­i­cal pro­gram fo­cus­es on reg­u­lat­ing im­mune cell me­tab­o­lism. And that’s where Lil­ly is step­ping on board, join­ing the pro­gram with an aim to ad­vance in­to hu­man stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER